Match tier
Institution-verified
Presence
Current · Arkansas
Last published
2026
Sources
Institutional record
Refreshed
2026-08-15
D
Daisy Alapat
Sourced from institutional research profiles (UAMS TRI or ARA).
Researcher
Also affiliated: University of Arkansas Medical Center (2025); Arkansas Department of Agriculture (2022)
Unknown Researcher
3 h-index
8 pubs
68 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Daisy Alapat's research focuses on hematologic malignancies, particularly multiple myeloma and Castleman disease. Her work investigates the immune microenvironment's role in disease progression and precursor stages, utilizing single-cell and multi-omics approaches. Alapat has contributed to studies characterizing the heterogeneity of Castleman disease, including findings from the ACCELERATE registry, and has examined treatment consistency with idiopathic multicentric Castleman disease guidelines for improved outcomes. Her research also explores the clinical implications of minimal residual disease negativity in multiple myeloma and the impact of specific gene expression, such as NEK2, on T-cell immunity in this context. Alapat is also involved in long-term follow-up studies of multiple myeloma treatment regimens, such as Total Therapy IIIB. She has a significant publication record with key collaborators at the University of Arkansas for Medical Sciences, including Fenghuang Zhan, Guido Tricot, Sharmilan Thanendrarajan, and John D. Shaughnessy.
Metrics
- h-index: 3
- Publications: 8
- Citations: 68
Selected Publications
-
Post‐transport macroscopic aggregates in a filtered bone marrow harvest bag (2026)
-
Illuminating Blurry Vision: Visualization of Corneal Protein Deposition With Immunofluorescence in Two Illustrative Case Reports (2026)
-
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)
-
Breast-implant associated unicentric castleman disease: a case report (2026)
-
Elucidating the grading intricacies of idiopathic multicentric Castleman disease histopathology: a pathologist’s perspective (2025)
-
Pediatric idiopathic multicentric castleman disease is often severe and responds to siltuximab (2025)
-
Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans (2025)
-
When less is more: the role of non-vitrectomized vitreous surgery in retinal diseases (2025)
-
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging (2025)
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)
-
Variable response rates across chemotherapy regimens for severe idiopathic multicentric Castleman disease. (2025)
-
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry (2025)
-
Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances (2025)
-
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)
-
The Development of Diagnostic Criteria and Utilization of Excisional Lymph Node Biopsies Shorten Time to Diagnosis for Idiopathic Multicentric Castleman Disease (2024)
Collaboration Network
Top Collaborators
Frits van Rhee
Winthrop Rockefeller Foundation
32 shared publications
In database
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Showing 5 of 32 shared publications
Carolina Schinke
University of Arkansas for Medical Sciences
24 shared publications
In database
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
Showing 5 of 24 shared publications
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
23 shared publications
In database
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
Showing 5 of 23 shared publications
Maurizio Zangari
Winthrop Rockefeller Foundation
22 shared publications
In database
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
Showing 5 of 22 shared publications
Samer Al Hadidi
Winthrop Rockefeller Foundation
18 shared publications
In database
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
Showing 5 of 18 shared publications
Clyde Bailey
Winthrop Rockefeller Foundation
14 shared publications
In database
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
Showing 5 of 14 shared publications
Cody Ashby
University of Arkansas for Medical Sciences
12 shared publications
In database
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
- A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
Showing 5 of 12 shared publications
John D. Shaughnessy
University of Arkansas for Medical Sciences
12 shared publications
In database
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
Showing 5 of 12 shared publications
Adam Bagg
University of Pennsylvania (US)
11 shared publications
- Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
- Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry
- Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease
- Characterization of Castleman Disease Reveals Patients with Oligocentric Adenopathy and Clinicopathologic Characteristics Similar to Unicentric Castleman Disease
- Characterizing Mortality Associated with Idiopathic Multicentric Castleman Disease
Showing 5 of 11 shared publications
Mary Jo Lechowicz
Emory University (US)
11 shared publications
- Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
- Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry
- Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease
- Characterization of Castleman Disease Reveals Patients with Oligocentric Adenopathy and Clinicopathologic Characteristics Similar to Unicentric Castleman Disease
- Characterizing Mortality Associated with Idiopathic Multicentric Castleman Disease
Showing 5 of 11 shared publications
Gordan Srkalović
Sparrow Health System (US)
11 shared publications
- Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
- Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry
- Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease
- Characterization of Castleman Disease Reveals Patients with Oligocentric Adenopathy and Clinicopathologic Characteristics Similar to Unicentric Castleman Disease
- Characterizing Mortality Associated with Idiopathic Multicentric Castleman Disease
Showing 5 of 11 shared publications
Guido Tricot
Winthrop Rockefeller Foundation
10 shared publications
In database
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
- A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
Showing 5 of 10 shared publications
Megan S. Lim
Kettering University (US)
10 shared publications
- Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
- Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry
- Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease
- Characterization of Castleman Disease Reveals Patients with Oligocentric Adenopathy and Clinicopathologic Characteristics Similar to Unicentric Castleman Disease
- Characterizing Mortality Associated with Idiopathic Multicentric Castleman Disease
Showing 5 of 10 shared publications
David E. Mery
Winthrop Rockefeller Foundation
10 shared publications
In database
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
- A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
- Prognostic Value of Ferritin in ASCT MM Patients: Integration with GEP Models and ISS Series Systems
Showing 5 of 10 shared publications
Eric R. Siegel
University of Arkansas for Medical Sciences
10 shared publications
In database
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
Showing 5 of 10 shared publications
Similar Researchers
Based on overlapping research topics
Y Yerramalla
University of Arkansas – Fort Smith
Immune Response and Inflammation
Disease Mechanisms Research
Medical Case Studies
B Poudel
University of Arkansas – Fort Smith
Immune Response and Inflammation
Disease Mechanisms Research
Medical Case Studies
Breanna Greaves
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Disease Mechanisms Research
Medical Case Studies
Manojna Konda
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Disease Mechanisms Research
Medical Case Studies
David E. Mery
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Immune Response and Inflammation
Disease Mechanisms Research
Hira Imad Cheema
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Immune Response and Inflammation
Medical Case Studies